Dashboard
Manage Tickers

AZNASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 79.58 $ 0.06 (0.08 %)    

Friday, 14-Jun-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 79.59
$ 79.42
$ 79.58 x 400
$ 0.00 x 0
$ 79.18 - $ 79.71
$ 59.55 - $ 80.86
2,055,322
na
124.32B
$ 0.56
$ 7.27
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

astrazeneca-reports-fda-approved-durvalumab-with-chemotherapy-for-mismatch-repair-deficient-primary-advanced-or-recurrent-endometrial-cancer
AstraZeneca Reports FDA Approved Durvaluma...
06/14/2024 20:13:39

-Reuters

Core News & Articles
FDA On June 13 Updates Advice To Manufactu...
06/14/2024 18:13:02

- Reuters

astrazenecas-farxiga-dapagliflozin-secures-fda-approval-to-improve-glycemic-control-in-pediatric-patients-with-type-2-diabetes-aged-10-years-and-older
AstraZeneca's FARXIGA (Dapagliflozin) Secu...
06/12/2024 21:38:35

The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. FARXIGA was previously approved in the...

astrazeneca-says-farxiga-has-been-approved-by-fda-to-improve-glycaemic-control-in-paediatric-patients-with-type-2-diabetes-aged-10-years-and-older
AstraZeneca Says Farxiga Has Been Approved...
06/12/2024 19:03:31

- Reuters

astrazeneca-says-farxiga-approved-in-us-for-treatment-of-paediatric-type-2-diabetes
AstraZeneca Says Farxiga Approved In U.S. ...
06/12/2024 19:02:19

- Reuters

astrrazeneca-announced-earlier-tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer
AstrraZeneca Announced Earlier Tagrisso Gr...
06/10/2024 09:04:59

AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) has been accepted and granted Priority Re...

Core News & Articles
FDA Advised Manufacturers Of Authorized Co...
06/07/2024 14:47:41

- Reuters

Core News & Articles
Novavax Says FDA Panel Backs Update For Mo...
06/05/2024 20:36:55

- Bloomberg

Core News & Articles
FDA Advisers Vote In Favor Of Recommending...
06/05/2024 18:51:23

- Reuters

heres-how-much-you-would-have-made-owning-astrazeneca-stock-in-the-last-5-years
Here's How Much You Would Have Made Owning...
06/04/2024 17:30:18

Core News & Articles
Reported Earlier, Daiichi Sankyo And Astra...
06/03/2024 06:49:46

DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody d...

astrazeneca-announced-tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo-in-laura-phase-iii-trial
AstraZeneca Announced Tagrisso Reduced The...
06/02/2024 18:25:18

Positive results from the LAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically si...

astrazeneca-announced-imfinzi-reduces-death-risk-by-27-vs-placebo-in-global-phase-iii-trial-in-limited-stage-small-cell-lung-cancer-with-57-survival-rate-at-three-years
AstraZeneca Announced Imfinzi Reduces Deat...
06/02/2024 14:16:21

Results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI®(durvalumab) ​demonstrated statistically significant and...

Core News & Articles
Fusion Pharmaceuticals Obtains Final Court...
05/31/2024 20:08:50

astrazeneca-ceo-says-no-need-for-further-mergers-and-acquisitions-inflation-reduction-act-could-impact-top-line-by-500m-pascal-soriot-aims-to-nearly-double-sales-by-2030-no-plans-to-retire
AstraZeneca CEO Says No Need For Further M...
05/31/2024 13:27:24

- Dow Jones Citing Interview

argus-research-maintains-buy-on-astrazeneca-raises-price-target-to-85
Argus Research Maintains Buy on AstraZenec...
05/30/2024 18:02:12

Argus Research analyst Jasper Hellweg maintains AstraZeneca (NASDAQ:AZN) with a Buy and raises the price target from $80 to ...

goldman-sachs-initiates-coverage-on-astrazeneca-with-buy-rating-announces-price-target-of-97
Goldman Sachs Initiates Coverage On AstraZ...
05/30/2024 10:46:05

Goldman Sachs analyst Rajan Sharma initiates coverage on AstraZeneca (NASDAQ:AZN) with a Buy rating and announces Price Targ...

Core News & Articles
Fusion Pharmaceuticals Shareholders Approv...
05/29/2024 20:10:23

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuga...

amgen-secures-fda-nod-for-rare-disease-treatment-biosimilar-based-on-astrazenecas-drug
Amgen Secures FDA Nod For Rare-Disease Tre...
05/29/2024 16:51:29

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare d...

why-is-astrazeneca-stock-trading-lower-on-tuesday
Why Is AstraZeneca Stock Trading Lower On ...
05/28/2024 18:32:38

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patient...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)